BOSTON--(BUSINESS WIRE)--MPM Capital today announced that William (Bill) C. Hahn, MD, PhD, will join its Oncology Impact Fund (OIF) Advisory Board. As a member of the OIF Advisory Board, Dr. Hahn will provide expert advice to support MPM’s strategy to build companies that seek to find cures for cancer.
Dr. Hahn is both a leading scientist and physician involved in biomedical research and in the care of cancer patients. His numerous groundbreaking discoveries have informed the current molecular understanding of cancer and have defined the tools, technologies and experimental models used to discover and validate targeted cancer therapies. Widely recognized for his work, Dr. Hahn was honored with the 2015 Richard and Hinda Rosenthal Award from AACR and the Ho-Am Prize in Medicine in 2010.
Dr. Hahn serves as a medical oncologist and Professor at Dana-Farber Cancer Institute and Harvard Medical School and is an Institute Member of the Broad Institute of MIT and Harvard. He is also the Chief Research Strategy Officer and the Chief of the Division of Molecular and Cellular Oncology in the Department of Medical Oncology at Dana-Farber Cancer Institute.
Raised jointly with UBS in 2015 and 2016, MPM’s OIF is a ~$500M impact fund dedicated to investing in cancer therapeutics. OIF invests across the spectrum of companies, from early-stage start-ups through public companies. OIF portfolio companies are developing transformative cancer therapeutics which will have a significant impact on patient outcomes and well-being. MPM has dedicated a portion of its own OIF profits to providing access to cancer care in the developing world and, in collaboration with AACR, to fund future innovation through academic cancer research.
“We’re thrilled to be able to work more closely with Bill in our quest to eradicate cancer,” stated Ansbert Gadicke, MPM Co-founder and Managing Director. “He is uniquely qualified to provide direction to the OIF. As a physician, he has a deep understanding of patients’ needs and as a researcher he has the cutting-edge scientific expertise to both help inform our investment decisions and translate scientific innovations into positive clinical outcomes.”
“I look forward to working in partnership with MPM and the OIF Advisory Board,” said Dr. Hahn. “I appreciate the OIF’s impact approach and share MPM’s bold objectives to cure cancers and discover next-generation treatments that save lives.”
Of his many other awards and professional affiliations, Dr. Hahn received the Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer and the Howard Temin Award from the National Cancer Institute; he has also served as President of the American Society for Clinical Investigation and was elected to the Association of American Physicians.
Dr. Hahn earned his MD and PhD from Harvard Medical School and his BA from Harvard University. He completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at Dana-Farber Cancer Institute, and conducted his postdoctoral studies in the lab of Robert Weinberg at the Whitehead Institute for Biomedical Research.
About MPM Capital — MPM Capital is an early-stage life sciences venture firm founding and investing in companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders and regenerative medicine. With its experienced and dedicated team of operating executives and medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patients’ lives. MPM is currently investing from two funds ─ the BV2014 and UBS Oncology Impact Fund (OIF). Dr. Hahn will serve as an advisor to the UBS OIF. For further information, please visit www.mpmcapital.com.